Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -0.56%86 3-Year EPS without NRI Growth Rate is 10.00% as of Apr. 2026, which is 21% below its 10-year median of 12.65. GuruFocus rates COO with a GF Score™ of 86/100 and a GF Value™ of $102.01 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 658 Medical Devices & Instruments companies, The Cooper ranks better than 53.04% on this metric.
During the past 12 months, The Cooper's average EPS without NRI Growth Rate was 17.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 10.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 9.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of The Cooper was 178.70% per year. The lowest was -53.90% per year. And the median was 12.65% per year.
The Cooper (NAS:COO) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
The Cooper 3-Year EPS without NRI Growth Rate Related Terms
COO vs BAX, SOLV, ALGN: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where The Cooper's 3-Year EPS without NRI Growth Rate falls into.
The Cooper 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 10.00% mean?
The Cooper (COO) has a 3-Year EPS without NRI Growth Rate of 10.00% as of Apr. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for The Cooper and its competitors. This is 21% below median its historical median of 12.65. According to the industry distribution chart, The Cooper ranks #309 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is The Cooper's 3-Year EPS without NRI Growth Rate too high?
The Cooper's current 3-Year EPS without NRI Growth Rate of 10.00% is 21% below median its 10-year median of 12.65. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. The Cooper's value of 10.00% is 26.6% above this industry median. Based on the distribution chart, The Cooper ranks #309 out of 658 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's 3-Year EPS without NRI Growth Rate compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #309 out of 658 companies for 3-Year EPS without NRI Growth Rate. This puts The Cooper in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.90. The Cooper's value of 10.00% is 26.6% above this benchmark. While the company's 10-year median is 12.65 vs. the industry median of 7.90, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current 3-Year EPS without NRI Growth Rate of 10.00% is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for The Cooper and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current 3-Year EPS without NRI Growth Rate is 10.00%, which is 21% below median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $102.01, compared to a current price of $69.70 — trading 31.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 10.00%, which is 21% below median its 10-year median of 12.65 and 26.6% above the Medical Devices & Instruments industry median of 7.90. The Cooper's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For The Cooper (COO), the current 3-Year EPS without NRI Growth Rate is 10.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $69.70 is trading 31.7% below its estimated GF Value™ of $102.01.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
3-Year EPS without NRI Growth Rate: 10.00% (21% below median its 10-year median of 12.65)
GF Value™: $102.01 vs. price of $69.70 (31.7% below fair value)
Industry Position: 26.6% above the Medical Devices & Instruments median (#309 of 658)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
86GF Score
Get the complete analysis for COO
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
